Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | HINT1 | P49773 | 4/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193423 | 0.92 | ADORA3 (0.55) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL26269037 | 0.91 | HINT1 (0.51) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL26269047 | 0.91 | HINT1 (0.51) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL12851760 | 0.89 | HPGD (0.45) | ADORA3HINT1NT5ETAAR1HPGD | |
| SCHEMBL562135 | 0.88 | ADORA3 (0.59) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL562134 | 0.88 | ADORA3 (0.59) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL25401067 | 0.86 | ADORA3 (0.51) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL15070633 | 0.86 | ADORA3 (0.51) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL22266762 | 0.85 | HINT1 (0.50) | ADORA3HINT1NT5ESTING1PDE3B | |
| SCHEMBL1375404 | 0.84 | ADORA3 (0.55) | ADORA3HINT1NT5ESTING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278425-B2 | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100249211-A1 | N-Substituted-Aminomethylene Bridged Bicyclic Nucleic Acid Analogs | IONIS PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249211-A1 | N-Substituted-Aminomethylene Bridged Bicyclic Nucleic Acid Analogs | NSUN2, RNMT, NSUN3 | ADORA3 1232/4885HINT1 656/4885NT5E 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.